Amgen And MBC BioLabs Announce Winners Of The Amgen Golden Ticket
The Pharma Data
SEPTEMBER 15, 2020
Our Trilomer® platform of peptidomimetic binders allows for the targeted inhibition of disease-causing proteins, for the treatment of cancer, autoimmune diseases, infectious diseases, and others. Each site has a complete molecular biology core facility that allows companies to do experiments on day one, not year one.
Let's personalize your content